Kontigo Care: Resilient top-line - Redeye

Redeye makes minimal estimate adjustments following the Q3’23 report, in which the reported figures were mainly in line with our estimates. While the present market conditions present ongoing challenges, we are optimistic that the new AI-based drug product has the potential to be a transformative innovation and a game changer for Kontigo Care. We have slightly adjusted our fair value range, primarily driven by the impact of increased interest rates.

Länk till analysen i sin helhet: https://www.redeye.se/research/947530/kontigo-care-resilient-top-line?utm_source=finwire&utm_medium=RSS